OrsoBio, a specialized biotechnology firm dedicated to pioneering treatments for obesity and its associated metabolic disorders, is strategically charting a…
Read More
Early Life Stress and the Gut-Brain Axis: New Research Identifies Critical Links Between Childhood Adversity and Chronic Digestive Disorders
The intricate connection between the human mind and the digestive system has long been a subject of medical inquiry, but…
Read More
OrsoBio’s LXR inverse agonist shows promise for hard-to-treat triglyceride disorders and pioneering a new frontier in obesity therapeutics
OrsoBio, a dynamic biotech enterprise dedicated to advancing novel therapies for obesity and a spectrum of obesity-related metabolic disorders, is…
Read More
Early Life Stress Linked to Long-Term Gut-Brain Interaction Disorders and Altered Sympathetic Nervous System Function
New scientific evidence published in the prestigious journal Gastroenterology has established a definitive link between early life adversity and the…
Read More
